brivoligide (AYX1) / Merck (MSD)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
brivoligide (AYX1) / Merck (MSD)
NCT01731730: Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

Completed
2
102
US
Placebo Injection, AYX1 Injection 110 mg, AYX1 Injection 330 mg
Adynxx, Inc.
Postsurgical Pain
10/13
11/13
NCT02081703: Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

Completed
2
120
US
AYX1 Injection 660 mg / 6 mL, AYX1 Injection 1100 mg / 10 mL, Placebo Injection 6 mL, Placebo Injection 10 mL
Adynxx, Inc.
Postsurgical Pain
06/15
06/15
NCT02807428: Study to Evaluate Safety/Efficacy of a Single Preop Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

Completed
2
210
US
AYX1 Injection 660 mg/6 mL, Brivoligide 660 mg/6 mL, Placebo Injection 6 mL
Adynxx, Inc.
Post-surgical Pain
10/17
12/17
NCT03797612: Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores

Withdrawn
2
0
US
Brivoligide Injection 660 mg/6 mL, AYX1 Injection 660 mg/6 mL, Placebo 6 mL
Adynxx, Inc.
Pain, Postoperative
01/22
02/22
NCT04104919: Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores

Withdrawn
2
0
NA
Brivoligide Injection 660 mg/6 mL, AYX1 Injection 660 mg/6 mL, Placebo 6 mL
Adynxx, Inc., National Institute on Drug Abuse (NIDA)
Pain, Postoperative
01/22
02/22

Download Options